U.S. Food and Drug Administration Approves an Autoinjector Version of LEROCHOL® (lerodalcibep-liga) and Updated Indication

CINCINNATI--(BUSINESS WIRE)--Aug 17, 2026-- LIB Therapeutics, Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced the U.S.